1. HBW Insight
  2. >>Wellness
  3. >>Business
  4. >>Earnings

COVID-19 Ibuprofen Fears Hit Advil Sales In GSK’s Q2

 
• By Tom Gallen

Reports that ibuprofen could worsen COVID-19 in the early months of the pandemic hit sales of GSK's leading Advil brand, contributing to a drop in pro-forma Consumer Healthcare turnover in the second quarter of 2020.

Munich, Bavaria / Germany - May 19, 2018: Headquarters of GlaxoSmithKline GmbH & Co. KG in Munich, Germany - GSK is a British pharmaceutical company
• Source: Shutterstock

Fears that ibuprofen could worsen COVID-19 infection which spread around the world in the early months of the pandemic hurt sales of GlaxoSmithKline plc’s power brand Advil.

Reporting the UK-based pharma player’s second-quarter results, GSK’s CFO Iain Mackay revealed “initial market misinformation relating to COVID-19 ibuprofen treatment” had led to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 
• By Malcolm Spicer

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

 
• By Malcolm Spicer

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.

Nestlé Health Science’s US VMS Recovery Stutters

 
• By Tom Gallen

US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.

US Q1 Consumer Health Earnings Preview: Concern Unavoidable For Impact From ‘T’ Word

 
• By Malcolm Spicer

Concern is unavoidable for most marketers of OTC drugs and dietary supplements in the US. As Canaccord Genuity analysts said in a 15 April research note, “uncertainty remains about how the tariff situation will play out.”

More from Business

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 
• By Malcolm Spicer

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

 
• By Malcolm Spicer

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By Tom Gallen

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.